FMP

FMP

Enter

THTX - Theratechnologies In...

photo-url-https://images.financialmodelingprep.com/symbol/THTX.png

Theratechnologies Inc.

THTX

NASDAQ

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

1.7 USD

-0.07 (-4.12%)

About

ceo

Mr. Paul Lévesque

sector

Healthcare

industry

Drug Manufacturers - Specialty & Generic

exchange

NASDAQ

Description

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

CIK

0001512717

ISIN

CA88338H7040

CUSIP

88338H100

Address

2015 Peel Street

Phone

15143367800

Country

CA

Employee

103

IPO Date

Feb 13, 2009

Key Executives

Name

Title

Pay

Year Born

Mr. Jocelyn Lafond L.L.M., LL.B.

General Counsel & Corporate Secretary

316.29k

1968

Mr. John Leasure

Global Commercial Officer

420.91k

1965

Mr. Paul Lévesque

President, Chief Executive Officer & Dir...

1.18M

1964

Hon. Andre Dupras M.Sc.

Vice President of Human Resources

0

1964

Mr. Philippe Dubuc M.B.A., MBA

Senior Vice President & Chief Financial ...

432.31k

1967

Dr. Christian Marsolais Ph.D.

Senior Vice President & Chief Medical Of...

434.61k

1963

As of December 31, 2024, the total employee count stands at 103, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep